Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)

William Camu1,2,3,4,5, Philippe Lehert1,2,3,4,5, Charles Pierrot‐Deseilligny1,2,3,4,5, Patrick Hautecœur1,2,3,4,5, Anne Besserve1,2,3,4,5, Anne-Sophie Jean Deleglise1,2,3,4,5, M. Payet1,2,3,4,5, Éric Thouvenot1,2,3,4,5, J.-C. Souberbielle1,2,3,4,5
1CHU Necker (J.C.S.), Paris, France.
2Faculty of Economics (P.L.), UCL Mons, Louvain, Belgium
3Faculty of Medicine (P.L.), the University of Melbourne, Australia
4From CHU Gui de Chauliac (W.C.) and Institut de Génomique Fonctionnelle (E.T.), Université de Montpellier, France; Faculty of Economics (P.L.), UCL Mons, Louvain, Belgium; Faculty of Medicine (P.L.), the University of Melbourne, Australia; CHU Pitié Salpêtrière (C.P.-D.), Paris; GHICL St Vincent de Paul (P.H.), Lille; Merck (A.B., A.-S.J.-D., M.P.), Lyon; CHU Caremeau (E.T.), Nîmes; and CHU Necker (J.C.S.), Paris, France.
5GHICL St Vincent de Paul (P.H.), Lille

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1111/ane.12712

10.1038/nrneurol.2016.188

10.1111/imm.12610

10.1016/S1474-4422(10)70086-7

10.1002/ana.21972

10.1002/ana.23591

10.1001/jamaneurol.2013.5993

10.1001/jamaneurol.2015.2742

10.1212/WNL.0b013e3181e1cec2

10.1016/j.msard.2017.03.014

10.1159/000345122

10.3109/08820139.2011.573041

10.1177/1352458511434607

10.1136/jnnp-2011-301876

10.1080/01616412.2016.1227913

10.1002/ana.20703

10.1001/jamaneurol.2014.3537

10.1007/s40120-017-0086-4

10.1212/WNL.0b013e31825fded9

10.1002/acn3.91

10.1371/journal.pone.0115488